Research On the Optimized Treatment Method For Apatinib's Cure Of Advanced Gastric Cancer

Sponsor
Anhui Provincial Hospital
Study ID
NCT03334591
Phase
PHASE2
Status
Unknown

Conditions

  • Two Different Treatment Methods

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib 500mg with Docetaxel 60mg/m2

Study Details

The investigators hope that after this research, two different treatment methods' curative effects for advanced gastric cancer can be assessed. One is continuous use of apatinib, the other is 5 days' continuous use and 2 days' off of apatinib.

Key Dates

Start date
Oct 1, 2017
Status verified
Oct 2017
Primary completion
Oct 1, 2019
Completion
Dec 1, 2019

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib 5 days' continuous use and 2 days' off
    Apatinib 500mg 5 days' continuous use and 2 days' off with Docetaxel60mg/m2 to treat advanced gastric cancer
  • Active Comparator: Apatinib 500mg continuous use
    Apatinib 500mg continuous use with Docetaxel60mg/m2 to treat advanced gastric cancer

Primary Outcome Measure

progress free survival(PFS) [ Time Frame: 1 year ]

Central Contacts